Skip to main content

Table 2 Core targets of Fuzhengkangai

From: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology

Uniprot accession

Gene names

Protein name

Log (Fold Change)

Adjust P value

P07550

ADRB2

Beta-2 adrenergic receptor

1.02

1.63e-17

P10415

BCL2

Apoptosis regulator Bcl-2

1.20

1.49e-9

P38936

CDKN1A

Cyclin-dependent kinase inhibitor 1

−1.01

4.79e-12

P28335

HTR2C

5-hydroxytryptamine receptor 2C

1.21

2.58e-16

Q12791

KCNMA1

Calcium-activated potassium channel subunit alpha-1

1.01

1.70e-8

P47712

PLA2G4A

Cytosolic phospholipase A2

−1.33

3.70e-8

P17252

PRKCA

Protein kinase C alpha type

1.06

3.69e-13

P61626

LYZ

Lysozyme C

1.91

4.52e-17